COVID-19 Results Briefing
Malta
June 13, 2022

This document contains summary information on the latest projections from the IHME model on COVID-19 in Malta. The model was run on June 8, 2022, with data through June 6, 2022.

Current situation

- Daily infections in the last week increased to 300 per day on average compared to 280 the week before (Figure 1.1). Daily hospital census in the last week (through June 6) decreased to seven per day on average compared to eight the week before.
- Daily reported cases in the last week increased to 93 per day on average compared to 77 the week before (Figure 2.1).
- Reported deaths due to COVID-19 in the last week remained the same at zero per day on average compared to the week before (Figure 3.1).
- Total deaths due to COVID-19 in the last week remained the same at one per day on average compared to the week before (Figure 3.1). This makes COVID-19 the number six cause of death in Malta this week (Table 1). Estimated total daily deaths due to COVID-19 in the past week were 1.5 times larger than the reported number of deaths.
- The daily rate of reported deaths due to COVID-19 is greater than 4 per million in no countries (Figure 4.1).
- The daily rate of total deaths due to COVID-19 is greater than 4 per million in two countries (Figure 4.2).
- We estimate that 68% of people in Malta have been infected at least once as of June 6 (Figure 6.1). Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 19 countries and five subnational locations. Effective R in Malta was 1.1 on May 26 (Figure 7.1).
- The infection-detection rate in Malta was close to 43% on June 6 (Figure 8.1).
- Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figures 9.1-9.5). We estimate that the Alpha variant is circulating in 51 countries and 59 subnational locations, that the Beta variant is circulating in 29 countries and 13 subnational locations, that the Delta variant is circulating in 51 countries and 60 subnational locations, that the Gamma variant is circulating in 26 countries and 22 subnational locations, and that the Omicron variant is circulating in 51 countries and 60 subnational locations.

Trends in drivers of transmission

- Mobility last week was 15% higher than the pre-COVID-19 baseline (Figure 11.1). Mobility was lower than 15% of baseline in one country (Figure 12.1).
- There were 282 diagnostic tests per 100,000 people on June 6 (Figure 15.1).
- As of June 6, 23 countries and 57 subnational locations have reached 70% or more of the population who have received at least one vaccine dose, and 20 countries and 53 subnational locations have reached 70% or more of the population who are fully vaccinated (Figures 17.1 and 17.2). 94% of people in Malta have received at least one vaccine dose, and 88% are fully vaccinated.
- In Malta, 99.1% of the population that is 12 years and older say they would accept a vaccine for COVID-19 (Figure 18.1). This is the same as the previous week. In Malta, 99.1% of the population that is 12 years and older say they would accept a vaccine for COVID-19 (Figure 18.1). This is the same as the previous week. The proportion of the population who are open to receiving a COVID-19 vaccine ranges from 35% in Kyrgyzstan to 99% in Iceland (Figure 19.1). Note that vaccine acceptance is calculated using survey data from the 18+ population.
As of May 30, 2022, zero percent of the population in Malta say they would accept a vaccine for COVID-19 but have not yet been vaccinated.

In our current reference scenario, we expect that 413,300 people will be vaccinated with at least one dose by October 1 (Figure 21.1). We expect that 88% of the population will be fully vaccinated by October 1.

**Projections and scenarios**

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace. Brand- and variant-specific vaccine efficacy is updated using the latest available information from peer-reviewed publications and other reports.
- Future mask use will decline to 50% of the minimum level it reached between January 1, 2021, and May 1, 2022. This decline begins after the last observed data point in each location and transitions linearly to the minimum over a period of six weeks.
- Mobility increases as vaccine coverage increases.
- 80% of those who have had two doses of vaccine (or one dose for Johnson & Johnson) receive a third dose at six months after their second dose.
- Antiviral utilization for COVID-19 risk prevention in high-risk populations will reach 80% between June 15, 2022, and July 31, 2022. This applies in high-income countries, but not low- and middle-income countries, and this rollout assumption follows a similar pattern to global vaccine rollouts.

The **80% mask use scenario** makes all the same assumptions as the reference scenario but assumes all locations reach 80% mask use within seven days. If a location currently has higher than 80% use, mask use remains at the current level.

The **antiviral access scenario** makes all the same assumptions as the reference scenario but assumes globally distributed antivirals and extends coverage to all low- and middle-income countries between August 15, 2022, and September 30, 2022.

**Infections**

- Daily estimated infections in the **reference scenario** will rise to 300 by June 8, 2022 (Figure 23.1).
- Daily estimated infections in the **80% mask use scenario** will decline to 10 by September 1, 2022 (Figure 23.1).
- Daily estimated infections in the **antiviral access scenario** will rise to 300 by June 8, 2022 (Figure 23.1).

**Cases**

- Daily estimated cases in the **reference scenario** will rise to 100 by June 11, 2022 (Figure 23.2).
- Daily estimated cases in the **80% mask use scenario** will decline to zero by September 17, 2022 (Figure 23.2).
- Daily estimated cases in the **antiviral access scenario** will rise to 100 by June 11, 2022 (Figure 23.2).

**Hospitalizations**

- Daily hospital census in the **reference scenario** will rise to 10 by June 21, 2022 (Figure 23.3). At some point from June through October 1, one country will have high or extreme stress on hospital beds (Figure 25.1). At some point from June through October 1, four countries will have high or extreme stress on intensive care unit (ICU) capacity (Figure 26.1).
- Daily hospital census in the **80% mask use scenario** will rise to 10 by June 8, 2022 (Figure 23.3).
- Daily hospital census in the **antiviral access scenario** will rise to 10 by June 21, 2022 (Figure 23.3).
Deaths

- In our reference scenario, our model projects 750 cumulative reported deaths due to COVID-19 on October 1. This represents 13 additional deaths from June 6 to October 1. Daily reported COVID-19 deaths in the reference scenario will decline to zero by September 14, 2022 (Figure 23.4).
- Under our reference scenario, our model projects 1,100 cumulative total deaths due to COVID-19 on October 1. This represents 19 additional deaths from June 6 to October 1 (Figure 23.5).
- In our 80% mask use scenario, our model projects 750 cumulative reported deaths due to COVID-19 on October 1. This represents seven additional deaths from June 6 to October 1. Daily reported COVID-19 deaths in the 80% mask use scenario will decline to zero by September 29, 2022 (Figure 23.4).
- In our antiviral access scenario, our model projects 750 cumulative reported deaths due to COVID-19 on October 1. This represents 13 additional deaths from June 6 to October 1. Daily reported COVID-19 deaths in the antiviral access scenario will decline to zero by September 14, 2022 (Figure 23.4).
- Figure 24.1 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.
Model updates

This month, we have made three alterations to our reference assumptions in the model. First, we expect the recent rollout of Paxlovid treatments in high-income settings to greatly reduce severe disease and death outcomes. We do not currently have data to inform levels of coverage, so we have introduced a simple scale-up model that assumes individuals over the age of 65 will be targeted for treatment, and access to treatment among this group will rise from 0% on June 15, 2022, to a maximum of 80% on July 31, 2022. Clinical trials suggest a Paxlovid provides an 88% reduction in the risk of hospitalization and death https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results among people treated within five days of symptom onset. We make a slightly more conservative assumption that the hospitalization and death rates will be reduced by 80% to account for variations in treatment timing and patient adherence in a real-world setting.

Second, survey data suggest that mask use is continuing to decline in most world locations. We have updated our reference mask use forecast to introduce a linear decline in mask use prevalence down to 50% of the minimum use level between January 1, 2021, and May 1, 2022, in each location. We have kept our previous assumption that mask use will continue at current levels in China, South Korea, Japan, Taiwan, Singapore, and South Africa, as current data do not suggest an imminent reduction.

Finally, similar to mask use, observed mobility continues to increase in much of the world. We have replaced our previous reference scenario that assumed current levels of mobility would persist indefinitely with a scenario that has mobility increase to match vaccine coverage. We continue to produce three scenarios when projecting COVID-19, but we have replaced the increased booster coverage scenario with an antiviral access scenario that examines the impact of more equitable distribution of Paxlovid to low- and middle-income countries (LMICs).
Figure 1.1: Daily COVID-19 hospital census and estimated infections

Figure 2.1: Reported daily COVID-19 cases, moving average
Table 1: Ranking of total deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>18</td>
<td>1</td>
</tr>
<tr>
<td>Stroke</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Alzheimer’s disease and other dementias</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung cancer</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>COVID-19</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Colon and rectum cancer</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>2</td>
<td>10</td>
</tr>
</tbody>
</table>

Figure 3.1: Smoothed trend estimate of daily COVID-19 deaths
Daily COVID-19 death rate per 1 million on June 6, 2022

**Figure 4.1:** Daily reported COVID-19 death rate per 1 million

**Figure 4.2:** Daily total COVID-19 death rate per 1 million
Cumulative COVID-19 deaths per 100,000 on June 6, 2022

Figure 5.1: Reported cumulative COVID-19 deaths per 100,000

Figure 5.2: Total cumulative COVID-19 deaths per 100,000
Figure 6.1: Estimated percent of the population infected with COVID-19 on June 6, 2022

Figure 7.1: Mean effective R on May 26, 2022. Effective R less than 1 means that transmission should decline, all other things being held the same. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past.
Figure 8.1: **Percent of estimated COVID-19 infections detected.** This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Due to measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particular points in time.
Estimated percent of circulating SARS-CoV-2 for primary variant families on June 6, 2022

Figure 9.1: Estimated percent of new infections that are Alpha variant

Figure 9.2: Estimated percent of new infections that are Beta variant
Figure 9.3: Estimated percent of new infections that are Delta variant

Figure 9.4: Estimated percent of new infections that are Gamma variant
Figure 9.5: Estimated percent of new infections that are Omicron variant

![Map showing the estimated percent of new infections that are Omicron variant across Europe.]
Figure 10.1: Infection-fatality rate on June 6, 2022. This is estimated as the ratio of COVID-19 deaths to estimated daily COVID-19 infections.
Critical drivers

Table 2: Current mandate implementation

<table>
<thead>
<tr>
<th>Mandate in place</th>
<th>Mandate imposed in some subnational locations (imposed this week)</th>
<th>No mandate (lifted this week)</th>
<th>No mandate (updated from previous reporting)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary school closure</td>
<td>Secondary school closure</td>
<td>Higher school closure</td>
<td>Entry restrictions for some non-residents</td>
</tr>
<tr>
<td>Albania</td>
<td>Andorra</td>
<td>Armenia</td>
<td>Austria</td>
</tr>
</tbody>
</table>

*Not all locations are measured at the subnational level.

covid19.healthdata.org Institute for Health Metrics and Evaluation
Figure 11.1: Trend in mobility as measured through smartphone app use, compared to January 2020 baseline

-75 | -50 | -25 | 0 | 25 | 25 | 0 | -25 | -50 | -75
Percent reduction from average mobility

- Russian Federation
- Malta
- United Kingdom
- Turkey
Figure 12.1: Mobility level as measured through smartphone app use, compared to January 2020 baseline (percent) on June 6, 2022
Figure 13.1: Trend in the proportion of the population reporting always wearing a mask when leaving home

Figure 14.1: Proportion of the population reporting always wearing a mask when leaving home on June 6, 2022
Figure 15.1: Trend in COVID-19 diagnostic tests per 100,000 people

Figure 16.1: COVID-19 diagnostic tests per 100,000 people on June 6, 2022
Table 3: Estimates of vaccine effectiveness for specific vaccines used in the model at preventing severe disease and infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our [website](https://covid19.healthdata.org).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Ancestral</th>
<th>Alpha</th>
<th>Beta</th>
<th>Gamma</th>
<th>Delta</th>
<th>Omicron</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Severe disease</td>
<td>Infection</td>
<td>Severe disease</td>
<td>Infection</td>
<td>Severe disease</td>
<td>Infection</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>94%</td>
<td>63%</td>
<td>94%</td>
<td>63%</td>
<td>94%</td>
<td>69%</td>
</tr>
<tr>
<td>CanSino</td>
<td>66%</td>
<td>62%</td>
<td>66%</td>
<td>62%</td>
<td>64%</td>
<td>61%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>50%</td>
<td>47%</td>
<td>50%</td>
<td>47%</td>
<td>49%</td>
<td>46%</td>
</tr>
<tr>
<td>Covaxin</td>
<td>78%</td>
<td>73%</td>
<td>78%</td>
<td>73%</td>
<td>76%</td>
<td>72%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>86%</td>
<td>72%</td>
<td>86%</td>
<td>72%</td>
<td>76%</td>
<td>64%</td>
</tr>
<tr>
<td>Moderna</td>
<td>97%</td>
<td>92%</td>
<td>97%</td>
<td>92%</td>
<td>97%</td>
<td>91%</td>
</tr>
<tr>
<td>Novavax</td>
<td>89%</td>
<td>83%</td>
<td>89%</td>
<td>83%</td>
<td>86%</td>
<td>82%</td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>95%</td>
<td>86%</td>
<td>95%</td>
<td>86%</td>
<td>95%</td>
<td>84%</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>73%</td>
<td>68%</td>
<td>73%</td>
<td>68%</td>
<td>71%</td>
<td>67%</td>
</tr>
<tr>
<td>Sputnik-V</td>
<td>92%</td>
<td>86%</td>
<td>92%</td>
<td>86%</td>
<td>89%</td>
<td>85%</td>
</tr>
<tr>
<td>Other vaccines</td>
<td>75%</td>
<td>70%</td>
<td>75%</td>
<td>70%</td>
<td>73%</td>
<td>69%</td>
</tr>
<tr>
<td>Other vaccines (mRNA)</td>
<td>91%</td>
<td>86%</td>
<td>91%</td>
<td>86%</td>
<td>88%</td>
<td>85%</td>
</tr>
</tbody>
</table>
Percent of the population having received at least one dose (17.1) and fully vaccinated against SARS-CoV-2 (17.2) by June 6, 2022

Figure 17.1: Percent of the population having received one dose of a COVID-19 vaccine

Figure 17.2: Percent of the population fully vaccinated against SARS-CoV-2
Figure 18.1: Trend in the estimated proportion of the population that is 12 years and older that has been vaccinated or would definitely receive the COVID-19 vaccine if available. Note that vaccine acceptance is calculated using survey data from the 18+ population.

Figure 19.1: Estimated proportion of the population that is 12 years and older that has been vaccinated or would definitely receive the COVID-19 vaccine if available. Note that vaccine acceptance is calculated using survey data from the 18+ population.
Figure 20.1: Estimated proportion of the total population that is not vaccinated but willing to be vaccinated as of May 30, 2022
Figure 21.1: Percent of people who receive at least one dose of a COVID-19 vaccine and those who are fully vaccinated

Figure 22.1: Percent of people who are immune to Delta or Omicron. Immunity is based on protection due to prior vaccination and infection(s). Moreover, variant-specific immunity is also based on variant-variant specific protection.
Projections and scenarios

Figure 23.1: Daily COVID-19 infections until October 01, 2022 for three scenarios

Figure 23.2: Daily COVID-19 reported cases until October 01, 2022 for three scenarios
Figure 23.3: Daily COVID-19 hospital census until October 01, 2022 for three scenarios
Figure 23.4: Reported daily COVID-19 deaths per 100,000
Figure 23.5: Total daily COVID-19 deaths per 100,000
Figure 24.1: Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available, last model update in brackets: Delphi from the Massachusetts Institute of Technology (Delphi) [May 29, 2022], and the SI-KJalpha model from the University of Southern California (SIKJalpha) [June 10, 2022]. Regional values are aggregates from available locations in that region.
Figure 25.1: The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and 20% or greater is considered extreme stress.
Figure 26.1: The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is considered moderate stress, 30-59% is considered high stress, and 60% or greater is considered extreme stress.
More information

Data sources:
Mask use and vaccine confidence data are from the The Delphi Group at Carnegie Mellon University and University of Maryland COVID-19 Trends and Impact Surveys, in partnership with Facebook. Mask use data are also from Premise, the Kaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.
Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:
We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:
For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.
To download our most recent results, visit our Data downloads page.